This study is currently not recruiting participants.

An Open-Label Extension Study to Evaluate the Safety Tolerability and Pharmacokinetics of STX209 (Arbaclofen) in Subjects with Fragile X Syndrome

Not Recruiting
100 years or below
Female
Phase N/A

Brief description of study.

The purpose of this study is to evaluate the safety, effectiveness, tolerability and pharmacokinetics (PK) of STX209 in subjects with fragile X syndrome over a long period of time.

Detailed description of study

The purpose of this study is to evaluate the safety, effectiveness, tolerability and pharmacokinetics (PK) of STX209 in subjects with fragile X syndrome over a long period of time.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Fragile X Syndrome
  • Age: 100 years or below
  • Gender: Female
Updated on 01 Feb 2013. Study ID: 1212010204

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team